Visão geral da empresa
A medical technology enterprise, STRATA Skin Sciences, Inc. focuses on the development, commercialization, and marketing of products designed to treat dermatologic conditions across a global footprint that includes the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates within the Healthcare sector, specifically within the Medical Devices industry, positioning it as a provider of specialized solutions for skin health rather than general pharmaceuticals or consumer goods. In terms of scale, the entity reports a market capitalization of $1.00M, generates annual revenue of $30.70M, and employs a workforce of 114 individuals. The combination of a market cap of $1.00M and revenue of $30.70M indicates a small-cap status where the market valuation is significantly lower than the revenue generation, suggesting a company that may be in a growth phase, facing structural challenges, or operating in a niche market where standard valuation multiples do not apply.
Saúde financeira
STRATA Skin Sciences, Inc. reports a trailing twelve-month revenue of $30.70M, a net income of -$6,261,000, and an EBITDA of -$1,712,000. The substantial gap between the positive revenue of $30.70M and the significant net loss of -$6,261,000 reveals a cost structure where operating expenses, likely driven by research and development or commercialization efforts, heavily outweigh gross profits, resulting in a profit margin of -20.4%. The company generates free cash flow of -$1,333,250, which indicates a current lack of financial flexibility as the business is burning cash rather than accumulating liquidity from operations. Despite the negative earnings, the firm holds cash reserves of $7.91M against total debt obligations of $16.27M, creating a net debt position that must be managed carefully. The balance sheet is highly leveraged, evidenced by a debt-to-equity ratio of 559.42, which implies a significant reliance on creditor financing relative to shareholder equity. Liquidity concerns are highlighted by a current ratio of 0.58, indicating that the company's current assets are insufficient to cover its current liabilities without additional financing or asset liquidation. Furthermore, the return on equity stands at -158.9% while the return on assets is -11.1%, metrics that reveal management has not yet generated positive returns on the capital invested by shareholders or the asset base, reflecting the ongoing operational losses.
Avaliação de valorização
The valuation metrics present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of -0.13. The forward P/E of -0.13, derived from negative earnings, implies that the market is not pricing the stock based on current profitability but rather on future expectations of earnings recovery or non-traditional valuation methods. The price-to-book ratio is 0.34, indicating that the market values the company at less than one-third of its net asset value, which suggests a significant discount relative to the book value or potential concerns regarding asset quality. Alternative valuation metrics such as the price-to-sales ratio of 0.03 and an EV/EBITDA of -5.47 suggest that the market is assigning a very low multiple to revenue, reflecting skepticism about the sustainability of the current revenue stream or high perceived risk. The stock price has fluctuated significantly, with a 52-week high of $3.86 and a 52-week low of $0.12. Trading relative to this range, the current price sits well below the 52-week high, reflecting the negative earnings trajectory and the high debt load mentioned in previous sections. The beta of 0.34 indicates that the stock price is less volatile than the broader market, moving only about one-third as much as the overall market index, which is unusual for a small-cap biotech or medical device firm that typically exhibits higher volatility.
Growth & Income
The company exhibits a revenue growth rate of -3.0% year-over-year, while earnings growth is listed as N/A due to the persistent net losses. The decline in revenue of -3.0% suggests a contraction in the business segment or market share, whereas the N/A status for earnings growth is a direct consequence of the company operating at a loss rather than generating profit to measure growth against. Since the company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders; instead, the company reinvests all available cash or relies on external financing to fund operations and growth initiatives. The overall growth and income profile is characterized by declining revenues and a complete absence of income distribution, highlighting a business model currently focused on survival and potential future market capture rather than immediate shareholder returns or consistent earnings expansion.